Skip to main content
Living With CMT2CHome

Resources

Conference videos: the 2026 sessions that matter for CMT2C

Two CMT conferences took place this fall, and both have put their recordings online for everyone. Here are the sessions I found most relevant to CMT2C, each with a short note, and the rest grouped by theme so you can find what interests you.

At a glanceThe CMT Research Foundation's Global CMT Research Convention (24 to 26 September 2026) and the Charcot-Marie-Tooth Association's Patient & Research Summit (9 to 11 October 2026) both heard a company update on the drug built for CMT2C, now called STAR-0871 (previously ABS-0871), and both had sessions on how clinical trials work, how the FDA judges CMT treatments, and how patients shape trial design. The recordings are free to watch [320] [323].

  • 24 to 26 September 2026 · Cambridge, Massachusetts

    2026 Global CMT Research Convention

    The CMT Research Foundation's yearly meeting: two days for researchers, clinicians and industry, then a Patient Experience Day on the Saturday [179]. On 29 October 2026 the foundation put all 48 talks online, each marked as patient-friendly or technical, on a free platform you can browse by topic [320] [321].

    Watch every session on the convention platform

  • 9 to 11 October 2026 · Redwood City, California

    2026 CMTA Patient & Research Summit

    The Charcot-Marie-Tooth Association's in-person weekend: a Saturday on living well with CMT and a Sunday on research, from discovery to delivery [322]. The CMTA posted recordings of 17 sessions on its YouTube channel in the two weeks after the summit [323].

    The CMTA's YouTube channel

Start here if you have CMT2C

A good place to start: the sessions that touch CMT2C most directly, in that order.

  1. Built for CMT2C

    Clinical trial updates from companies: Dr. David Goldstein (Actio Biosciences, now Setara)

    CMTRF convention, Saturday 26 September 2026

    The company update on the TRPV4 blocker developed for CMT2C, given four weeks before the company launched as Setara Biosciences (spun out of Actio Biosciences) and renamed the drug STAR-0871 (previously ABS-0871) [318]. It was part of the Clinical Trials Updates Session on Patient Day, where companies said where their programs stand [179]. Dr. Goldstein founded Actio and is Setara's president and executive chair [319]. Why this drug matters to us.

    Watch on YouTube Session page

  2. Built for CMT2C

    Clinical trials: the industry perspective

    CMTA summit, Sunday 11 October 2026 · 41 minutes

    A panel with the companies developing CMT treatments, including Dr. Goldstein for Actio Biosciences (now Setara), on where their programs stand, the challenges they face, how decisions are made about who can take part, and how the CMTA and the patient community are helping [322].

    Watch on YouTube

  3. Our community

    The patient voice in clinical trials

    CMTA summit, Sunday 11 October 2026 · 33 minutes

    Dr. Katherine Forsey, the CMTA's chief research officer, with patients from the NMD Pharma trial, the SORD trial, the ACT-CMT study and the CMT2C patient group, on what taking part in research is really like [322].

    Watch on YouTube

  4. The FDA

    FDA and CMT: how the FDA thinks about CMT evaluation

    CMTRF convention, Saturday 26 September 2026 · Dr. Teresa Buracchio, US Food and Drug Administration

    How regulators evaluate potential CMT therapies [321]. Useful background for anyone following the FDA listening session for our community on 20 October and the road ahead for STAR-0871.

    Watch on YouTube Session page

  5. Natural history

    Why visit an Inherited Neuropathy Consortium site

    CMTRF convention, Saturday 26 September 2026 · Dr. Vera Fridman, University of Colorado

    The INC's natural history study is open to every type of CMT and is where the 2025 TRPV4 registry data came from [52] [3]. This talk explains what a visit involves and why it matters for trials. How to join.

    Watch on YouTube Session page

Global CMT Research Convention (CMTRF), 24 to 26 September 2026

Thursday and Friday were designed for scientists, clinicians and investors, Saturday for patients [179]. The platform marks each talk as patient-friendly or technical and lets you browse by subject [320]. Beyond the picks above, these sessions are the ones I would point a CMT2C family to.

Getting ready for trials

  • Patient-friendly

    What to expect in a clinical trial

    Jenneen DeFiore, PPD (part of Thermo Fisher Scientific) · Saturday

    Screening, study visits and what a typical trial day looks like, step by step [321].

    Watch on YouTube

  • Patient-friendly

    How I chose to participate in a clinical trial

    Paul-Andre Archambalt and Peter DeSilva · Saturday

    A firsthand account from people who have been through a CMT trial [321].

    Watch on YouTube

  • Patient-friendly

    Patient perspectives to inform therapeutic development and trial design

    Patient forum moderated by Susan Ruediger, CMTRF · Friday

    Researchers designing the next CMT trials hear directly from the patients those trials are meant to serve [321].

    Watch on YouTube

  • Patient-friendly

    Many roads to treating Charcot-Marie-Tooth disease

    Dr. Meghan Drummond, CMT Research Foundation · Saturday

    A survey of the whole pipeline, from small molecules to gene therapy, listed on the program as “The rest of the pipeline” [179].

    Watch on YouTube

  • Patient-friendly

    The pros and cons of genetic testing

    Dr. Marina Kennerson, ANZAC Research Institute and University of Sydney · Saturday

    Trials recruit by subtype, so a confirmed genetic diagnosis is the first step [53]. Reading a TRPV4 result.

    Watch on YouTube

Measuring what matters in CMT2C

The TRPV4 registry authors wrote that standard CMT scales miss the uneven weakness, the vocal fold weakness and the breathing involvement of our disease, and called for outcome measures that capture them [3]. These Friday talks are about exactly that problem, for CMT as a whole.

  • Technical

    Clinical outcome measures and biomarkers for CMT: are we ready for clinical trials?

    Dr. Vera Fridman, University of Colorado · Friday

    Watch on YouTube

  • Technical

    Beyond patient-reported outcomes: defining meaningful clinical endpoints in CMT

    Dr. Bopha Chrea, University of Iowa · Friday

    Watch on YouTube

  • Technical

    DANCER: a new, patient-partnered platform for clinical trials in CMT

    Dr. Wolfgang Pernice, Columbia University Irving Medical Center · Friday

    Movement analysis from smartphone video. A patient-friendly version, “Using AI to build better outcome measurements”, was given on the Saturday [179].

    Watch on YouTube Saturday version

  • Technical

    Clinical trial endpoints: discussion panel

    Moderated by Dr. Brett McCray, University of Michigan · Friday

    Dr. McCray is a TRPV4 researcher and the first author of the GeneReviews chapter on TRPV4-related disorders [6].

    Watch on YouTube

Hearing, and a CMT2C biomarker project

  • Patient-friendly

    Hearing and CMT

    Dr. Ronna Hertzano, University of Maryland and National Institutes of Health · Saturday

    Partial hearing loss was reported by 27% of people in the TRPV4 registry [3]. A technical version of the talk was given on the Thursday.

    Watch on YouTube Technical version

  • Technical

    Profiling neurovascular cells for biomarker discovery

    Jonathan Alevy, Johns Hopkins University · Thursday

    The CMTRF-funded project looking for changes in the cells that line nerve blood vessels in a lab model of CMT2C, part of the search for a blood test that could track the disease [99]. More on the biomarker work.

    Watch on YouTube

Treatments for other axonal forms of CMT

None of these is for CMT2C, but each tackles a form of CMT in which, as in ours, the nerve fiber itself is damaged. The Trials page explains which of them could one day matter for us.

  • Technical

    Development of RTX-117, an eIF2B activator targeting the integrated stress response across diverse CMT subtypes

    Dr. Sridhar Narayan, ReviR Therapeutics · Friday, and a company update on Saturday

    RTX-117 is in the “could work, ask the researchers” group on Trials and research.

    Session page Saturday company update

  • Technical

    In vivo testing of CRISPR-Cas9 gene therapy approaches in a mouse model of CMT2E

    Dr. Abigail Tadenev, Jackson Laboratory · Friday

    Watch on YouTube

  • Technical

    N-of-1 personalized therapy for CMT2S: from preclinical models to first-in-human dosing

    Dr. Sandra Smieszek, Vanda Pharmaceuticals · Friday

    Watch on YouTube

Browse all 48 convention talks

CMTA Patient & Research Summit, 9 to 11 October 2026

The summit was in person only, at the Grand Bay Hotel in Redwood City, with NMD Pharma as presenting sponsor [322]. The recordings are on the CMTA's YouTube channel; the CMTA's own conference recordings page had not yet listed them when I checked on 31 October 2026 [323]. Besides the two panels in my picks above, these are worth watching.

Sunday: research, from discovery to delivery

  • Trial readiness

    Our commitment to investing in clinical trial readiness: the CMTA–INC partnership

    Dr. Michael Shy, University of Iowa, and Dr. Sue Bruhn, CMTA · 28 minutes

    A fireside chat on what it takes to bring a CMT treatment from the lab to a trial, how trials work, why they take time and what decides who can take part, with the presentation of the Mike Shy Lifetime Achievement Award [322].

    Watch on YouTube

  • Already open to CMT2

    Targeting shared pathways: treatments that could help many people with CMT

    Daniel Brennan, NMD Pharma, and Dr. Jordan VerPlank, Uniformed Services University · 24 minutes

    NMD Pharma's ignaseclant was tested in adults with CMT1 or CMT2 [45]; see how it acts.

    Watch on YouTube

  • Pipeline

    Targeting the root cause

    Dr. Luke Judge, UCSF Benioff Children's Hospital, and Catherine Illingworth, Kylix Bio · 30 minutes

    Genetic therapies and which subtypes they may target [322].

    Watch on YouTube

  • Pipeline

    Delivery science: the missing link in CMT treatments

    Dr. John Svaren, Dr. Rachel Salzman and Dr. Brian Price · 22 minutes

    Watch on YouTube

  • Our community

    Keynote address: a patient's experience of a clinical trial

    Cara Leath, CMT community member · 19 minutes

    Watch on YouTube

Saturday: living well with CMT

  • Everyday life

    Center of Excellence clinic teams

    Dr. Alexander Fay and Dr. Madina Tugizova, UCSF; Dr. John Day, Stanford · 50 minutes

    What a CMT Center of Excellence does, with open questions from the room. Find a center.

    Watch on YouTube

  • Everyday life

    Genetic testing for CMT

    Carly Siskind, genetic counselor, Stanford · 30 minutes

    Watch on YouTube

  • Everyday life

    Pain management strategies for CMT

    Dr. John Day, Stanford · 37 minutes

    Half of TRPV4 registry participants reported arthritic-like pain [3]; see Pain and mental health.

    Watch on YouTube

  • Everyday life

    Staying active with CMT: PT, OT and gadgets

    Natalie Anzures, physical therapist, and Jessica Mok, occupational therapist, UCSF · 38 minutes

    Pairs well with the Movement guide.

    Watch on YouTube

  • Everyday life

    Patient panel: stories of living well with CMT

    Dr. Julie FitzGerald and Erin Weierbach · 42 minutes

    Watch on YouTube

All summit recordings on the CMTA channel

What I am still adding

How this page was made. The descriptions above come from the two published programs and the video titles, not from a transcript of each talk, so they say what a session is about, not what was said in it. I am watching the sessions in my picks first and will add notes here on anything new for CMT2C, such as the timing of the STAR-0871 trial. Neither conference had a session on CMT2C breathing or voice problems; for those, our own Breathing and voice page and the CMTA's 2024 session on CMT-related breathing issues remain the best places to start.

  • The FDA listening session. On 20 October 2026 the FDA heard from people with CMT2C and their families in a private session organized by the CMTA [104]. The FDA's list of listening session summaries shows ours with the note “summary coming soon” [324]. I will link it from Why ABS-0871 matters as soon as it appears.
  • The CMTA's recordings page. The CMTA keeps past summit sessions on its conference recordings page, which still ends at 2024 [325]. When the 2026 sessions move there, I will update the links.
  • Earlier videos. The December 2025 CMT2C/TRPV4 meeting with Actio Biosciences and the CMT Research Foundation's two talks on CMT2C by Dr. McCray are listed on the resource directory.

Also new on this site

  • ABS-0871 has a new name. On 30 October 2026 Setara Biosciences (spun out of Actio Biosciences) launched as the company developing the drug, now called STAR-0871 (previously ABS-0871), with a trial in people with CMT2C planned for 2027 [318] [319]. Why it matters to us and where it stands.

Next: Questions